Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.25    0.00 (0.00%)
Bid:
6.00
Ask:
6.50
Spread: 0.50 (8.333%)
Market Cap: £6.46m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Commercial Appointments

1 Mar 2022 07:00

RNS Number : 0988D
OptiBiotix Health PLC
01 March 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Commercial Appointments

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces the following appointments1: Zac Sniderman as Business Development & Sales Director North America, Shiraz Butt as E-Commerce Director and Karl Burkitt as Marketing Director.

 

Zac brings a broad experience developing a food and supplement ingredient businesses in North America working for Galenicum Speciality Ingredients, Jarrow Formulas and Best Ground International. He has an entrepreneurial mindset and an extensive network. He will focus on the development of ingredient sales to brand owners and contract manufacturers for both pro- and prebiotics in close cooperation with our established partners.

 

Shiraz has successfully developed the e-commerce businesses for a range of companies, such as PhD (now part of Science In Sports) and Iovate Health Sciences. He has built digital sales from the ground up into significant contributors to the success of the companies he has worked for. Shiraz will focus on developing the untapped e-commerce potential of our pro- and prebiotic brands such as SlimBiome Medical, Go-Figure and CholBiome.

 

Karl Burkitt has a rich career in which he developed and led the marketing and business development function in various branded and ingredient businesses, such as Novartis Consumer Health, Kerry Ingredients & Flavours and AB Mauri. Karl will lead our marketing function, on a part time basis, and work closely with the pro- and prebiotic commercial divisions on developing ingredient and consumer sales.

 

The above appointments expand the capabilities of our management team in line with our commercial strategy, which is to further expand ingredient sales, particularly in the large North American market, whilst developing our final product sales containing our unique ingredients.

 

René Kamminga, CEO of OptiBiotix Ltd, commented: "In the past 12 months we have established the credibility and brand awareness of our science-based ingredients SlimBiome®, OptiBiome, LeanBiome and LPLDL® ingredients, significantly growing sales to a wider number of reputable global brands in multiple markets. These appointments are a further investment to accelerate the growth of the Company and to broaden and deepen our income streams with a particular focus on North America and E-Commerce."

 

1These appointments are non-statutory director appointments in the Company or its subsidiaries.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATPMRTMTJTBAT
Date   Source Headline
2nd Jun 20267:00 amRNS-RInvestor presentation and SweetBiotix® Sampling
29th May 20267:00 amRNSDirector/PDMR Shareholding
28th May 20267:00 amRNSFinal Results & Notice of AGM
14th May 20267:00 amRNS-RSweetBiotix® Sampling
5th May 20262:30 pmRNSHolding(s) in Company
1st May 202612:00 pmRNSPartial Disposal of Shares in SkinBioTherapeutics
1st Apr 20267:00 amRNSTrading Update
24th Feb 20267:00 amRNSWellBiome® clinical trial on surgical outcomes
17th Feb 20267:00 amRNSStatement: SkinBioTherapeutics Announcement
21st Jan 20267:00 amRNSLarge Order and Record Early Orders for 2026
20th Jan 20267:00 amRNS-RNew Investor Website
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
24th Nov 20257:00 amRNSSweetBiotix Overview and Update
17th Nov 20257:00 amRNSOrder with well-known Weight Management Company
13th Oct 20253:31 pmRNSHolding(s) in Company
2nd Oct 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 202512:28 pmRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHalf-year Report
21st Aug 20257:00 amRNSAdmission to Trading on the OTCQB Venture Market
20th Aug 20257:00 amRNSAgreement with Weight Management Company
14th Aug 20257:00 amRNSLaunch of SlimBiome in leading US brand
6th Aug 20254:08 pmRNSResult of AGM
6th Aug 20257:00 amRNSIssue of Options
28th Jul 20257:00 amRNSTrading update
30th Jun 20257:00 amRNSChange of Broker
30th Jun 20257:00 amRNSFinal Results
11th Jun 20257:00 amRNS-RSlimBiome® study in European Journal of Nutrition
23rd May 20257:00 amRNSPlacing and Issue of Warrants
20th May 20257:00 amRNSLaunch of SlimBiome products with US partner
15th Apr 20257:00 amRNSFirst order from US weight management brand
7th Apr 20255:34 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSCommercial Update
18th Feb 20257:00 amRNSLaunch of Daily Nouri FeelFull product in America
20th Jan 20257:00 amRNS-RLaunch of products on Amazon India
8th Jan 20257:00 amRNSDirectorate Change
20th Dec 202412:00 pmRNSIssue of Options
12th Dec 20242:45 pmRNSHolding(s) in Company
3rd Dec 20247:00 amRNSLaunch of Dr Morepen LightLife in India
30th Oct 20247:00 amRNSRequisition update
25th Oct 20244:29 pmRNSHolding(s) in Company
24th Oct 20247:00 amRNSTotal Voting Rights
23rd Oct 20247:00 amRNSDirectorate Change
18th Oct 20247:00 amRNSResponse to Publication of Circular by ProBiotix
10th Oct 20247:00 amRNSSlimBiome study update
27th Sep 20247:00 amRNSHalf-year Report
26th Sep 20247:00 amRNSResponse to Probiotix Health requisition notice
5th Sep 202410:32 amRNSProBiotix Health plc Fundraise
20th Aug 20247:00 amRNSCommercial update
8th Aug 202412:29 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.